Leadership transition at the largest Australasian healthcare distributor

MedTech & Diagnostics News: After 11 years at the helm of EBOS Devices, including LifeHealthcare, EBOS MedTech, and its subsidiaries Transmedic Group, Australian Biotechnologies, and Cryomed Aesthetics, Matt Muscio will step down as CEO in August. Muscio’s expertise will be retained in a proposed new role as a non-executive board member of EBOS Group.

“We will be welcoming Andrew McLean into the position of CEO for EBOS MedTech in August and looking with anticipation towards continuing to build on the strong foundations that Matt and the leadership team have created,” stated the company, the largest Australasian wholesaler and distributor of healthcare, medical and pharmaceutical products. 

McLean brings over 25 years of experience in the medical device and pharmaceutical industries, having successfully driven growth across several global businesses. His expertise spans strategic planning and operations, sales and marketing, product and service innovation, and mergers and acquisitions. McLean’s career has seen him based in various locations across Australia, Asia, and North America.

EBOS Chair Liz Coutts commented, “EBOS would be very fortunate to retain Matt with his significant skills and experience, particularly in the healthcare sectors in Australia, New Zealand, and Southeast Asia. Following our annual meeting, we look forward to welcoming Matt to the Board.”

Earlier this year, Muscio sold 100% of his EBOS Group shares, a substantial NZ$5.3m worth of stock. This was the biggest sale of company shares made by an insider individual in the last twelve months.

Reflecting on his journey, Muscio said “So proud of what we’ve achieved collectively and excited to embark on a new chapter, centred on family, as we relocate to Central Otago, New Zealand.

“I’ve been blessed to work with brilliant people during this time, forming many lifelong friendships. Talented clinicians who’ve generously shared their knowledge, global medtech innovators who’ve partnered to positively impact patients’ lives, investors and Board members who’ve backed me through good times and bad, and company founders who’ve trusted me in joining our group to build something unique.”

In line with EBOS’ Board renewal process, independent director Peter Williams will retire at the conclusion of the 2024 Annual Meeting. Williams’ retirement is part of a carefully considered succession plan that has included the appointments of Mark Bloom and Julie Tay as independent directors over the past two years, as well as the newly proposed appointment of Matt Muscio. Williams has been a director since 2013.

EBOS Chair Liz Coutts added, “Peter has dedicated 11 years to the EBOS Board and over that time has made an enormous contribution, having joined the Board following EBOS’ acquisition of Symbion – a pivotal time for our company. Peter has also been universally acknowledged as a respected source of counsel and support to our senior management teams over the years.

“During his tenure as a director, EBOS has generated significant growth and shareholder value, and on behalf of the Board and our shareholders, I sincerely thank Peter and wish him all the very best in his retirement.”

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.